Larazotide Acetate

Phase 2Small molecule

99 Meters Biopharma, Inc.

Larazotide Acetate is one of 56 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Celiac DiseaseActive, not recruiting

COVID-19Phase 2

Active, not recruiting

Celiac DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Activella

Eli Lilly

Preclinical

—3

Larazotide Acetate

99 Meters Biopharma, Inc.

Phase 2

1 4

Rayaldee

OOrganon and Co

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Olokizumab

UCB

Preclinical

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Long COVID

NCT05747534

Clinical

Trials by Indication[1]

Celiac Disease6 trials

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

Completed·99 Meters Biopharma, Inc.·Phase 2·NCT00492960·171 enrolled

Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects

Completed·99 Meters Biopharma, Inc.·Phase 2·NCT00362856·80 enrolled

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Completed·99 Meters Biopharma, Inc.·Phase 2·NCT00620451·105 enrolled

Show 3 more trials

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Completed·99 Meters Biopharma, Inc.·Phase 2·NCT00889473·42 enrolled

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Completed·99 Meters Biopharma, Inc.·Phase 2·NCT01396213·342 enrolled

Safety Study of Larazotide Acetate to Treat Celiac Disease.

Completed·99 Meters Biopharma, Inc.·Phase 1·NCT00386165·21 enrolled

Long COVID1 trial

AT1001 for the Treatment of Long COVID

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05747534·150 enrolled

COVID-191 trial

AT1001 for the Treatment of COVID-19 Related MIS-C

Terminated·MMassachusetts General Hospital·Phase 2·NCT05022303·12 enrolled

Unspecified1 trial

Safety of Larazotide Acetate in Healthy Volunteers

Completed·99 Meters Biopharma, Inc.·Phase 1·NCT00386490·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Larazotide Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Larazotide Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Larazotide Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — 9 Meters Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: 99 Meters Biopharma, Inc.

Larazotide Acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Celiac Disease6 trials

Long COVID1 trial

COVID-191 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News